Adagrasib, a RAS GTPase inhibitor, has shown promise in improving progression-free survival and overall response rate in adults with KRASG12C-mutated non-small cell lung cancer, according to results from a phase 3 trial. The drug received accelerated FDA approval for use in previously treated patients. The study found that adagrasib was superior to standard chemotherapy, meeting its primary endpoint of PFS and key secondary endpoint of ORR. Safety data remained consistent with the drug’s established profile. The results of the KRYSTAL-12 trial will be shared with regulatory authorities and presented at a medical conference, providing a new targeted treatment option for patients with this specific mutation.
Source link
Krazati slows disease progression in certain patients with lung cancer
